Viking Therapeutics (VKTX) Gains Ahead Of Earnings As Its Obesity Narrative Keeps Fair Value In Focus
Viking Therapeutics (VKTX) recently gained 1.43% in the latest trading session, outpacing the broader market. The move comes as investors look ahead to an expected loss per share of US$1 in the upcoming earnings report.
Viking Therapeutics shares have seen a 22.57% 90 day share price return and a 4.06% 30 day share price return, while the year to date share price return is slightly down 1.55%. However, the 1 year total shareholder return of 29.24% and the very large 5 year total shareholder return suggest momentum has built over longer periods, even as near term sentiment shifts around upcoming earnings and recent clinical updates.
Compare Viking Therapeutics' momentum with a curated group of fast moving biotech opportunities drawn from our 19 high quality undiscovered gems.
For Viking Therapeutics, that 1.43% move can look like fresh conviction in the drug pipeline or just short term sentiment around an expected loss. To judge it properly, the next step is the valuation.
Most Popular Narrative: 72.1% Undervalued
The most followed narrative on Viking Therapeutics pegs fair value at $125 against a last close of $34.87. That gap rests on aggressive obesity drug assumptions and a long runway of clinical execution.
The oral VK2735 program, supported by Phase II data with double digit weight loss percentages and plans to move into Phase III, gives Viking a second high value product path that may diversify future revenue sources and create operating leverage if both oral and injectable share the same active molecule.
Want to see what justifies that kind of upside for Viking Therapeutics? The narrative leans on bold revenue ramps, margin expansion and a premium earnings multiple. Curious how those pieces fit together into one valuation story?
Result: Fair Value of $125 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Viking Therapeutics still faces key risks, including widening losses with higher R&D spend, as well as the chance that VK2735 trials or regulatory feedback disrupt the bullish valuation story.
Find out about the key risks to this Viking Therapeutics narrative.
Another View on Viking Therapeutics' Valuation
The bullish fair value of $125 for Viking Therapeutics leans heavily on long range obesity drug forecasts and future earnings. Yet the stock currently trades at a P/B of 10x compared with 4.8x for peers and 2.5x for the wider US Biotechs industry. That richer multiple signals less margin for error if the growth story disappoints. How comfortable are you paying a premium price for a company that is still pre revenue?
For a closer look at how this premium P/B ratio compares with peers in practical terms, take a few minutes with the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Feeling uncertain about whether the enthusiasm around Viking Therapeutics matches the risks on the table? Move quickly, review the full risk profile, and weigh those concerns for yourself with the 3 important warning signs
Looking for more ideas beyond Viking Therapeutics?
Do not stop your research with Viking Therapeutics. Broaden your watchlist now with a few focused stock ideas that could sharpen your next move.
- Target potential mispricings by scanning companies that combine quality fundamentals with attractive valuations using the 47 high quality undervalued stocks.
- Strengthen your income stream by reviewing companies with higher yields and resilient payout histories through the 11 dividend fortresses.
- Reduce portfolio stress by focusing on companies that score well on financial stability and risk metrics with the 82 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com